Literature DB >> 22156850

The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization.

Danuta M Skowronski1, Naveed Z Janjua, Elodie P Sonfack Tsafack, Manale Ouakki, Linda Hoang, Gaston De Serres.   

Abstract

BACKGROUND: Parental immunization has been recommended as a "cocoon" strategy to prevent serious pertussis outcomes in early infancy. We illustrate the high number needed to vaccinate (NNV) for this program based on recent epidemiologic data from the provinces of Québec and British Columbia (BC), Canada.
METHODS: Surveillance trends were summarized for the period 1990-2010. Hospitalization, intensive care unit (ICU) admission, and mortality data were compiled from 2000 to 2009. The proportion of infant pertussis attributed to a parent was estimated at 35%, explored up to 55%. Adult vaccine efficacy (VE) was estimated at 85%. The NNV was calculated as [2 parents/(parent-attributable infant risk × parent VE)]. To capture at least 1 recent cyclical peak, NNV was derived for the period 2005-2009 and explored for peak/trough years.
RESULTS: Substantial decline has occurred in pertussis incidence across all age groups including infants, reaching a 20-year nadir in 2010 in both provinces. For the period 2005-2009, the risk of infant hospitalization and ICU admission was 57 and 7, respectively, per 100 000 in Québec and 33 and 7, respectively, per 100 000 in BC. In both provinces the risk of infant pertussis-related death over that period was <0.5 per 100 000. The NNV for parental immunization was at least 1 million to prevent 1 infant death, approximately 100 000 for ICU admission, and >10 000 for hospitalization.
CONCLUSIONS: In the context of low pertussis incidence, the parental cocoon program is inefficient and resource intensive for the prevention of serious outcomes in early infancy. Regions contemplating the cocoon program should consider the NNV based on local epidemiology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156850     DOI: 10.1093/cid/cir836

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  25 in total

1.  Seroprevalence of pertussis in China: need to improve vaccination strategies.

Authors:  Yinghua Xu; Lichan Wang; Jin Xu; Xinjian Wang; Chen Wei; Peng Luo; Xiao Ma; Qiming Hou; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2013-09-09       Impact factor: 3.452

2.  The benefits of influenza vaccine in pregnancy for the fetus and the infant younger than six months of age.

Authors:  Noni E MacDonald; Jane C McDonald
Journal:  Paediatr Child Health       Date:  2014-12       Impact factor: 2.253

3.  Potential impact of parental Tdap immunization on infant pertussis hospitalizations.

Authors:  Timothy R Peters; Gretchen C Banks; Beverly M Snively; Katherine A Poehling
Journal:  Vaccine       Date:  2012-06-27       Impact factor: 3.641

Review 4.  Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

5.  Protecting infants from pertussis.

Authors:  Meghan Gilley; Ran D Goldman
Journal:  Can Fam Physician       Date:  2014-02       Impact factor: 3.275

Review 6.  Pertussis.

Authors:  Giovanni Gabutti; Chiara Azzari; Paolo Bonanni; Rosa Prato; Alberto E Tozzi; Alessandro Zanetti; Gianvincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 7.  Pertussis re-emergence in the post-vaccination era.

Authors:  Elena Chiappini; Alessia Stival; Luisa Galli; Maurizio de Martino
Journal:  BMC Infect Dis       Date:  2013-03-26       Impact factor: 3.090

8.  Tdap vaccination during pregnancy to reduce pertussis infection in young infants.

Authors:  Jeremy N Matlow; Anna Pupco; Pina Bozzo; Gideon Koren
Journal:  Can Fam Physician       Date:  2013-05       Impact factor: 3.275

9.  Randomized clinical trial of the safety and immunogenicity of the Tdap vaccine in pregnant Mexican women.

Authors:  Jesús Zacarías Villarreal Pérez; José Manuel Ramírez Aranda; Manuel de la O Cavazos; Michelle de J Zamudio Osuna; José Perales Dávila; María Romelia Ballesteros Elizondo; Marco Vinicio Gómez Meza; Francisco Javier García Elizondo; Azucena M Rodríguez González
Journal:  Hum Vaccin Immunother       Date:  2017-01-02       Impact factor: 3.452

10.  Surveillance of hospitalized and outpatient cases of pertussis in Catalonia from 2003 to 2009.

Authors:  Inma Crespo Fernández; Núria Soldevila; Gloria Carmona; Maria Rosa Sala; Pere Godoy; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-09       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.